Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre

被引:103
作者
Chen, M
Yu, F
Zhang, Y
Zhao, MH [1 ]
机构
[1] Peking Univ, Hosp 1, Div Renal, Beijing 100034, Peoples R China
[2] Peking Univ, Hosp 1, Inst Nephrol, Beijing 100034, Peoples R China
关键词
D O I
10.1136/pgmj.2005.034215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Antineutrophil cytoplasmic autoantibodies (ANCA) are serological markers of ANCA associated systemic vasculitides (AASV), which is one of the most common multisystem autoimmune diseases. Features of Chinese patients with AASV have not been fully investigated. Objective: To analyse the clinical and pathological characteristics of Chinese patients with AASV. Methods: 426 Chinese patients with AASV diagnosed in the past eight years were retrospectively studied and their clinical and pathological data were analysed. Results: Of the 426 patients, 87 (20.4%) were Wegener's granulomatosis, 337 (79.1%) were microscopic polyangiitis and two (0.5%) were Churg-Strauss syndrome. Only 201 of 426 (47.2%) patients were diagnosed within three months. Clinically, the patients had multisystem involvement. Altogether 371 of 426 (87.1%) had kidney involvement and 260 of 426 (61.0%) had lung involvement. The prevalences of renal involvement and fatigue were significantly higher in patients with MPO-ANCA than that in patients with PR3-ANCA; the prevalences of ophthalmic, nasal involvement, rash, and arthragia were significantly higher in patients with PR3-ANCA than those in patients with MPO-ANCA. The one and five year death rates were 13.1% and 22.4%, respectively. The percentage of patients progressing to end stage renal disease at one and five years was 15.9% and 27.1%, respectively. Conclusions: AASV is not a rare autoimmune disease in Chinese people. Kidney and lung were the most vulnerable organs. For patients with multiorgan damage, an ANCA test should be performed to make an early diagnosis and to start treatment in time.
引用
收藏
页码:723 / 727
页数:5
相关论文
共 24 条
[1]   Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis [J].
Bajema, IM ;
Hagen, EC ;
Hermans, J ;
Noël, LH ;
Waldherr, R ;
Ferrario, F ;
van der Woude, FJ ;
Bruijn, JA .
KIDNEY INTERNATIONAL, 1999, 56 (05) :1751-1758
[2]   Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study [J].
Booth, AD ;
Almond, MK ;
Burns, A ;
Ellis, P ;
Gaskin, G ;
Neild, GH ;
Plaisance, M ;
Pusey, CD ;
Jayne, DRW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) :776-784
[3]  
Franssen C, 1998, J INTERN MED, V244, P209
[4]   Antiproteinase 3-and antimyeloperoxidase-associated vasculitis [J].
Franssen, CFM ;
Stegeman, CA ;
Kallenberg, CGM ;
Gans, ROB ;
de Jong, PE ;
Hoorntje, SJ ;
Tervaert, JWC .
KIDNEY INTERNATIONAL, 2000, 57 (06) :2195-2206
[5]   The epidemiology of the primary systemic vasculitides in the northwest Spain: Implications of the Chapel Hill Consensus Conference definitions [J].
Gonzalez-Gay, MA ;
Garcia-Porrua, C ;
Guerrero, J ;
Rodriguez-Ledo, P ;
Llorca, J .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2003, 49 (03) :388-393
[6]   Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis [J].
Hagen, EC ;
Daha, MR ;
Hermans, J ;
Andrassy, K ;
Csernok, E ;
Gaskin, G ;
Lesavre, P ;
Lüdemann, J ;
Rasmussen, N ;
Sinico, RA ;
Wiik, A ;
van der Woude, FJ .
KIDNEY INTERNATIONAL, 1998, 53 (03) :743-753
[7]   Renal histology in ANCA-associated vasculitis:: Differences between diagnostic and serologic subgroups [J].
Hauer, HA ;
Bajema, IM ;
van Houwelingen, HC ;
Ferrario, F ;
Noël, LH ;
Waldherr, R ;
Jayne, DRW ;
Rasmussen, N ;
Bruijn, JA ;
Hagen, EC .
KIDNEY INTERNATIONAL, 2002, 61 (01) :80-89
[8]   WEGENER GRANULOMATOSIS - AN ANALYSIS OF 158 PATIENTS [J].
HOFFMAN, GS ;
KERR, GS ;
LEAVITT, RY ;
HALLAHAN, CW ;
LEBOVICS, RS ;
TRAVIS, WD ;
ROTTEM, M ;
FAUCI, AS .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (06) :488-498
[9]   Limited versus severe Wegener's granulomatosis - Baseline data on patients in the Wegener's granulomatosis etanercept trial [J].
Hopkins, J ;
Stone, JH ;
Uhlfelder, ML ;
Moore, AM ;
Hoffman, GS ;
Holbrook, JT ;
Meinert, CL ;
Dodge, J ;
Donithan, J ;
Min, N ;
Murrow, L ;
Smith, J ;
Tibbs, AK ;
Van Natta, M ;
Spiera, R ;
Berman, R ;
Enuha, S ;
Merkel, PA ;
Gelbard, R ;
Nuite, M ;
Schiller, A ;
Blumenthal, D ;
Bork, D ;
Clark, T ;
Crook, SL ;
Calabrese, LH ;
Farkas, S ;
Sridharan, S ;
Strom, K ;
Wilke, W ;
St Clair, EW ;
Allen, NB ;
Rodin, K ;
Scarlett, E ;
Hellmann, DB ;
Pinachos, L ;
Regan, MJ ;
Specks, U ;
Bradt, K ;
Carlson, K ;
Fisher, S ;
Hammel, B ;
Mieras, K ;
Ytterberg, S ;
Davis, JC ;
Fitzpatrick, M ;
Fye, K ;
Lund, S ;
McCune, J ;
Coomer, BJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2299-2309
[10]   NOMENCLATURE OF SYSTEMIC VASCULITIDES - PROPOSAL OF AN INTERNATIONAL CONSENSUS CONFERENCE [J].
JENNETTE, JC ;
FALK, RJ ;
ANDRASSY, K ;
BACON, PA ;
CHURG, J ;
GROSS, WL ;
HAGEN, EC ;
HOFFMAN, GS ;
HUNDER, GG ;
KALLENBERG, CGM ;
MCCLUSKEY, RT ;
SINICO, RA ;
REES, AJ ;
VANES, LA ;
WALDHERR, R ;
WIIK, A .
ARTHRITIS AND RHEUMATISM, 1994, 37 (02) :187-192